Carregant...

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia

Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rizzo, Manfredi, Battista Rini, Giovam
Format: Artigo
Idioma:Inglês
Publicat: Termedia Publishing House 2011
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3258692/
https://ncbi.nlm.nih.gov/pubmed/22291726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2011.20597
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!